tiprankstipranks
Trending News
More News >
Femasys (FEMY)
NASDAQ:FEMY
US Market

Femasys (FEMY) AI Stock Analysis

Compare
343 Followers

Top Page

FE

Femasys

(NASDAQ:FEMY)

Rating:44Neutral
Price Target:
$1.00
▲(7.53%Upside)
The overall stock score reflects significant financial and operational challenges, balanced by some positive corporate developments. The financial instability and potential delisting are major concerns, whereas recent regulatory approvals offer potential growth opportunities. Investors should weigh these factors carefully.
Positive Factors
Market Expansion
FemaSeed is now being offered in more than 60 clinics across the U.S., which could allow for quick patient access.
Partnerships
Strategic distribution partnerships in Spain are set to drive the initial FemBloc launch, with additional EU partnerships expected soon.
Regulatory Approval
FemBloc system receives EU approval, clearing it for commercial launch in select markets, starting with Spain.
Negative Factors
Commercial Performance
Overall sales in 1Q25 were $0.34M, which were much lower than our estimate of $1.5M.
Market Competition
Greater-than-expected commercial competition for any of the company’s programs, given other treatments on the market or in development.
Revenue Estimates
We have lowered our 2025 revenue based on the slower than expected ramp up, and now estimate revenues of $5.3M compared to our prior estimate of $10M.

Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)

Femasys Business Overview & Revenue Model

Company DescriptionFemasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
How the Company Makes MoneyFemasys makes money primarily through the development and commercialization of its medical devices and technologies. The company's revenue streams are mainly derived from the sale of its proprietary products, such as FemBloc, a non-surgical permanent birth control solution, and FemVue, an infertility diagnosis product. Femasys may also engage in strategic partnerships and licensing agreements with healthcare providers and distributors to expand the reach of its products, contributing to its revenue. The company's earnings are influenced by the demand for its innovative solutions in women's health and its ability to successfully navigate regulatory approvals and market competition.

Femasys Financial Statement Overview

Summary
Femasys is facing financial headwinds with persistent losses and cash flow issues. Revenue growth is overshadowed by operational inefficiencies and financial instability. Improving financial health and achieving profitability are crucial for future sustainability.
Income Statement
35
Negative
Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.
Balance Sheet
40
Negative
The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.
Cash Flow
30
Negative
Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.70M1.63M1.07M1.21M1.18M1.04M
Gross Profit1.13M1.08M691.90K764.28K809.30K731.38K
EBITDA-18.54M-16.33M-13.17M-10.49M-6.55M-5.80M
Net Income-21.11M-18.82M-14.25M-11.39M-7.54M-6.91M
Balance Sheet
Total Assets0.0012.45M27.76M16.90M28.58M7.61M
Cash, Cash Equivalents and Short-Term Investments0.003.45M21.72M12.96M24.78M3.32M
Total Debt7.67M7.44M6.70M543.72K990.21K2.06M
Total Liabilities1.44M10.14M9.40M1.65M2.24M59.42M
Stockholders Equity2.00M2.30M18.35M15.24M26.33M-51.82M
Cash Flow
Free Cash Flow-20.50M-20.21M-11.42M-11.14M-8.24M-4.96M
Operating Cash Flow-19.64M-19.44M-11.28M-10.73M-7.93M-4.93M
Investing Cash Flow-854.21K-847.76K-143.92K-407.48K-306.87K968.32K
Financing Cash Flow6.48M2.03M20.18M-681.64K29.70M871.65K

Femasys Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.93
Price Trends
50DMA
1.00
Negative
100DMA
1.20
Negative
200DMA
1.17
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
48.26
Neutral
STOCH
28.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.93 is above the 20-day moving average (MA) of 0.90, below the 50-day MA of 1.00, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 28.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Risk Analysis

Femasys disclosed 74 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Femasys Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$13.13M1.157.10%-0.19%-18.41%
59
Neutral
HK$15.37B5.69-7.44%4.08%11.55%-28.15%
44
Neutral
$30.23M-239.87%61.97%-6.89%
RVRVP
44
Neutral
$19.69M-25.89%-16.05%-195.28%
44
Neutral
$53.36M-88.36%-9.13%30.04%
43
Neutral
$19.59M-138.80%-14.41%-549.88%
42
Neutral
$7.59M-504.16%-31.31%49.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FEMY
Femasys
0.92
-0.18
-16.36%
HBIO
Harvard Bioscience
0.44
-2.34
-84.17%
RVP
Retractable Technologies
0.66
-0.50
-43.10%
MLSS
Milestone Scientific
0.68
-0.03
-4.23%
POAI
Predictive Oncology
0.85
-0.18
-17.48%
MHUA
Meihua International Medical Technologies Co., Ltd.
0.41
-0.56
-57.73%

Femasys Corporate Events

Private Placements and Financing
Femasys Enters Purchase Agreement with Alumni Capital
Neutral
Jul 3, 2025

On June 30, 2025, Femasys Inc. entered into a Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock over a specified period. This agreement provides Femasys with flexibility in financing, contingent on market conditions and trading prices, while ensuring compliance with regulatory requirements and ownership limitations.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Product-Related AnnouncementsRegulatory Filings and Compliance
Femasys Gains Regulatory Approvals in Australia and New Zealand
Positive
Jul 1, 2025

On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Femasys Approves Director Elections and Share Increase
Neutral
Jun 25, 2025

On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximately 59.41% of the total outstanding shares were represented. During the meeting, stockholders approved the election of two Class I directors, an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000, and ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Femasys Gains European Approval for FemBloc System
Positive
Jun 25, 2025

On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Femasys Appoints Kelley Nicholas as Chief Commercial Officer
Positive
Jun 17, 2025

On June 17, 2025, Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer to lead the U.S. commercialization of fertility products and expand global partnerships. Ms. Nicholas, with over 25 years of industry experience, is expected to drive revenue growth and strengthen Femasys’ position in women’s health. The company also granted her an option to purchase 100,000 shares of common stock as an inducement for her employment.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Femasys Announces Public Offering and Private Placement
Neutral
Jun 2, 2025

On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at $0.85 per share. The company also initiated a concurrent private placement with existing institutional stockholders and certain directors and officers, raising a total of approximately $4.5 million before expenses. The proceeds are intended for commercial expansion, product development, and general corporate purposes. Additionally, Femasys agreed to establish a $10 million equity line of credit with Alumni Capital LP by June 30, 2025, with potential penalties if not completed.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Delistings and Listing Changes
Femasys Receives Nasdaq Delisting Notice for Low Market Value
Negative
May 23, 2025

On May 19, 2025, Femasys received a notice from Nasdaq indicating that the market value of its listed securities had fallen below the required $35 million for continued listing on the Nasdaq Capital Market. The company has until November 17, 2025, to regain compliance, or it may face delisting. Femasys plans to actively monitor its market value and explore options to meet the requirement, although there is no assurance of success.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025